Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation
Hongjiao Wang, He Jiang, Songlin He, Songwen Ren, Haiwen Li, Wangnan Liu, Chunyun Zhou, Pan Zhu, Keren Chen, Weijia Cao, Yan Qin, Dan Du, Nengming Xiao, Hongling Huang, Chun-Jung Ko, Yiming Zheng, Bo Wang, Qiang Zou, Jian-Hong Shi, Xun Li, Zuliang Jie
Hongjiao Wang, He Jiang, Songlin He, Songwen Ren, Haiwen Li, Wangnan Liu, Chunyun Zhou, Pan Zhu, Keren Chen, Weijia Cao, Yan Qin, Dan Du, Nengming Xiao, Hongling Huang, Chun-Jung Ko, Yiming Zheng, Bo Wang, Qiang Zou, Jian-Hong Shi, Xun Li, Zuliang Jie
View: Text | PDF
Research Article Cell biology Immunology

DYRK1A enhances antitumor immunity in type 1 conventional dendritic cells via mTORC1 activation

  • Text
  • PDF
Abstract

Type 1 conventional dendritic cells (cDC1s) play an integral role in mediating immune responses and maintaining homeostasis, yet the molecular mechanisms underlying their functions remain poorly understood. In this study, we identified dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) as a key kinase that responded to TLR and growth factor stimulation and acted as an essential regulator of cDC1 function. Genetic ablation of Dyrk1a specifically in cDC1s impaired antitumor immunity and accelerated tumor progression in murine models. Mechanistically, DYRK1A mediated the phosphorylation of the mTOR complex 1 (mTORC1) inhibitor TSC2 at serine 540, triggering the degradation of TSC2 and promoting mTORC1 signaling in cDC1s. Notably, Tsc2 deletion in Dyrk1a-deficient cDC1s remarkably restored their antitumor immune functions. Furthermore, DYRK1A-mediated mTORC1 signaling in cDC1s positively correlated with effector T cell responses across multiple human cancers. Our findings highlight a critical role for the DYRK1A/TSC2/mTORC1 signaling pathway in regulating cDC1 functions in antitumor immunity, offering potential strategies to improve cancer immunotherapy.

Authors

Hongjiao Wang, He Jiang, Songlin He, Songwen Ren, Haiwen Li, Wangnan Liu, Chunyun Zhou, Pan Zhu, Keren Chen, Weijia Cao, Yan Qin, Dan Du, Nengming Xiao, Hongling Huang, Chun-Jung Ko, Yiming Zheng, Bo Wang, Qiang Zou, Jian-Hong Shi, Xun Li, Zuliang Jie

×

Figure 3

DYRK1A activates the mTORC1 signaling pathway in DCs.

Options: View larger image (or click on image) Download as PowerPoint
DYRK1A activates the mTORC1 signaling pathway in DCs.
(A) Functional enr...
(A) Functional enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways significantly changed in Dyrk1a-deficient DCs compared with wild-type DCs. (B) Immunoblot analysis of indicated proteins in whole-cell lysates of tumor DCs from wild-type and Dyrk1a-DC-cKO mice. (C) Flow cytometric analysis of p-S6 in tumor-infiltrating DCs freshly isolated from tumor-bearing wild-type and Dyrk1a-DC-cKO mice. Wild-type mice: N = 8; Dyrk1a-DC-cKO mice: N = 11. (D) Flow cytometric analysis of p-S6 in DCs isolated from tumor or tumor-draining lymph nodes (N = 10 mice/group). 4EBP1, eukaryotic translation initiation factor 4E-binding protein 1. (E) Immunoblot analysis of indicated proteins in whole-cell lysates of BMDCs stimulated with Poly(I:C) at the indicated time points. (F and G) Immunoblot analysis of the indicated proteins and phosphorylated (p-) proteins in whole-cell lysates of BMDCs stimulated with amino acids (F) and EGF (G). (H) Extracellular acidification rate (ECAR) of DCs stimulated with Poly(I:C) for 4 hours under basal conditions (Bas) or at maximum (Max) with the addition of glucose (Glu), oligomycin (Oli), and 2-deoxy-d-glucose (2-DG). Data are representative of 3 independent experiments. Summary data are shown as the mean ± SEM. P values were determined using a 2-tailed unpaired Student’s t test. ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts